Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy.
Maria Salgado; S Alireza Rabi; Karen A O'Connell; Robert W Buckheit; Justin R Bailey; Amina A Chaudhry; Autumn R Breaud; Mark A Marzinke; William Clarke; Joseph B Margolick; et al. (Profiled Authors: William Clarke; Joel Blankson; Joseph Margolick; Robert Siliciano)
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
Retrovirology 2011;8():97.
BACKGROUND: While initiation of highly active antiretroviral therapy (HAART) during primary HIV-1 infection occasionally results in transient control of viral replication after treatment interruption, the vast majority of patients eventually experience a rebound in plasma viremia. RESULTS: Here we report a case of a patient who was started on HAART during symptomatic primary infection and who has subsequently maintained viral loads of < 50 copies/mL for more than nine years after the cessation of treatment. This patient had a high baseline viral load and has maintained a relatively high frequency of latently infected CD4(+) T cells. In addition, he does not have any known protective HLA alleles. Thus it is unlikely that he was destined to become a natural elite controller or suppressor. The mechanism of control of viral replication is unclear; he is infected with a CCR5/CXCR4 dual-tropic virus that is fully replication-competent in vitro. In addition, his spouse, who transmitted the virus to him, developed AIDS. The patient's CD4(+) T cells are fully susceptible to HIV-1 infection, and he has low titers of neutralizing antibodies to heterologous and autologous HIV-1 isolates. Furthermore, his CD8(+) T cells do not have potent HIV suppressive activity. CONCLUSION: This report suggests that some patients may be capable of controlling pathogenic HIV-1 isolates for extended periods of time after the cessation of HAART through a mechanism that is distinct from the potent cytotoxic T lymphocyte (CTL) mediated suppression that has been reported in many elite suppressors.
Scientific Context
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Related Publications
-
1.
2007Deborah Persaud; Stuart C Ray; Joleen Kajdas; Aima Ahonkhai; George K Siberry; Kimberly Ferguson; Carrie Ziemniak; Thomas C Quinn; Joseph P Casazza; Steven Zeichner; et al.
AIDS research and human retroviruses 2007;23(3):381-90. -
2.
1997D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; et al.
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
Science (New York, N.Y.) 1997;278(5341):1295-300. -
3.
2003Anding Shen; M Christine Zink; Joseph L Mankowski; Karen Chadwick; Joseph B Margolick; Lucy M Carruth; Ming Li; Janice E Clements; Robert F Siliciano
Journal of virology 2003;77(8):4938-49.
Related Topics
Appears in this Publication
Related Experts
Author of this Publication
-
Internal ExpertsPublications
-
219









-
272









-
71









-
615









-
49









-
41










